Investors & Media
Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and cancer-supportive care by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancer and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizer’s palbociclib (Ibrance®) for the treatment of MDM2-amplified advanced solid tumors, and in a Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities.More >>
|Data as of
Copyright West LLC. Minimum 15 minutes delayed.